165 related articles for article (PubMed ID: 11269233)
1. In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea.
Sierra JM; Ruiz J; Navia MM; Vargas M; Vila J
Antimicrob Agents Chemother; 2001 Feb; 45(2):643--4. PubMed ID: 11269233
[No Abstract] [Full Text] [Related]
2. In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea.
Ruiz J; Mensa L; O'Callaghan C; Pons MJ; González A; Vila J; Gascón J
Diagn Microbiol Infect Dis; 2007 Dec; 59(4):473-5. PubMed ID: 17889485
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of rifaximin against bacterial enteropathogens causing diarrhoea in children under 5 years of age in Ifakara, Tanzania.
Sierra JM; Navia MM; Vargas M; Urassa H; Schellemberg D; Gascón J; Vila J; Ruiz J
J Antimicrob Chemother; 2001 Jun; 47(6):904-5. PubMed ID: 11389133
[No Abstract] [Full Text] [Related]
4. In vitro activity and fecal concentration of rifaximin after oral administration.
Jiang ZD; Ke S; Palazzini E; Riopel L; Dupont H
Antimicrob Agents Chemother; 2000 Aug; 44(8):2205-6. PubMed ID: 10898704
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of rifaximin against clinical isolates of Escherichia coli and other enteropathogenic bacteria isolated from travellers returning to the UK.
Hopkins KL; Mushtaq S; Richardson JF; Doumith M; de Pinna E; Cheasty T; Wain J; Livermore DM; Woodford N
Int J Antimicrob Agents; 2014 May; 43(5):431-7. PubMed ID: 24661532
[TBL] [Abstract][Full Text] [Related]
6. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions.
Gomi H; Jiang ZD; Adachi JA; Ashley D; Lowe B; Verenkar MP; Steffen R; DuPont HL
Antimicrob Agents Chemother; 2001 Jan; 45(1):212-6. PubMed ID: 11120968
[TBL] [Abstract][Full Text] [Related]
7. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders.
Adachi JA; DuPont HL
Clin Infect Dis; 2006 Feb; 42(4):541-7. PubMed ID: 16421799
[TBL] [Abstract][Full Text] [Related]
8. Treatment of travelers' diarrhea.
DuPont HL
J Travel Med; 2001 Dec; 8(Suppl 2):S31-3. PubMed ID: 12186671
[No Abstract] [Full Text] [Related]
9. In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler's diarrhea and Clostridium difficile.
Farrell DJ; Putnam SD; Biedenbach DJ; Moro L; Bozzella R; Celasco G; Jones RN
Antimicrob Agents Chemother; 2011 Mar; 55(3):992-6. PubMed ID: 21149623
[TBL] [Abstract][Full Text] [Related]
10. Antibacterial chemoprophylaxis in the prevention of traveler's diarrhea: evaluation of poorly absorbed oral rifaximin.
DuPont HL; Jiang ZD; Okhuysen PC; Ericsson CD; de la Cabada FJ; Ke S; DuPont MW; Martinez-Sandoval F
Clin Infect Dis; 2005 Dec; 41 Suppl 8():S571-6. PubMed ID: 16267721
[TBL] [Abstract][Full Text] [Related]
11. Rifaximin (Xifaxan) for traveler's diarrhea.
Keenum AJ; Stockton MD
Am Fam Physician; 2005 Dec; 72(12):2525-6. PubMed ID: 16370411
[No Abstract] [Full Text] [Related]
12. Rifamycin SV MMX for the treatment of traveler's diarrhea.
Lin SW; Lin CJ; Yang JC
Expert Opin Pharmacother; 2017 Aug; 18(12):1269-1277. PubMed ID: 28697313
[TBL] [Abstract][Full Text] [Related]
13. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial.
DuPont HL; Jiang ZD; Ericsson CD; Adachi JA; Mathewson JJ; DuPont MW; Palazzini E; Riopel LM; Ashley D; Martinez-Sandoval F
Clin Infect Dis; 2001 Dec; 33(11):1807-15. PubMed ID: 11692292
[TBL] [Abstract][Full Text] [Related]
14. Bile acids improve the antimicrobial effect of rifaximin.
Darkoh C; Lichtenberger LM; Ajami N; Dial EJ; Jiang ZD; DuPont HL
Antimicrob Agents Chemother; 2010 Sep; 54(9):3618-24. PubMed ID: 20547807
[TBL] [Abstract][Full Text] [Related]
15. Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections.
Cottreau J; Baker SF; DuPont HL; Garey KW
Expert Rev Anti Infect Ther; 2010 Jul; 8(7):747-60. PubMed ID: 20586560
[TBL] [Abstract][Full Text] [Related]
16. [Bacterially induced traveler's diarrhea. Local antibiosis effective without systemic effects].
MMW Fortschr Med; 2008 Nov; 150(45):48-9. PubMed ID: 19058391
[No Abstract] [Full Text] [Related]
17. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea.
Taylor DN; Bourgeois AL; Ericsson CD; Steffen R; Jiang ZD; Halpern J; Haake R; Dupont HL
Am J Trop Med Hyg; 2006 Jun; 74(6):1060-6. PubMed ID: 16760520
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth.
Pistiki A; Galani I; Pyleris E; Barbatzas C; Pimentel M; Giamarellos-Bourboulis EJ
Int J Antimicrob Agents; 2014 Mar; 43(3):236-41. PubMed ID: 24461710
[TBL] [Abstract][Full Text] [Related]
19. The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review.
DuPont HL
Clin Microbiol Rev; 2023 Dec; 36(4):e0003923. PubMed ID: 37971270
[TBL] [Abstract][Full Text] [Related]
20. Traveler's diarrhea.
Yates J
Am Fam Physician; 2005 Jun; 71(11):2095-100. PubMed ID: 15952437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
